The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Your Contributions (include, but are not limited to): Lead analytical development and characterization activities for peptides, antibodies, and bioconjugates, using techniques such as capillary electrophoresis, iCIEF, LC (e.g., RP, SEC, IEX), mass spectrometry, and other relevant characterization technologies.